Stand Up for Science traces 40 years of HIV treatment progress

Stand Up for Science has published the 10th installment of its weekly “Traces Thursday” series, this time on HIV treatment and prevention. The case study highlights how four decades of research turned HIV from a fatal diagnosis into a manageable chronic condition, while an effective vaccine still remains out of reach.

Why it matters: - The HIV story shows how long-term basic research can produce major medical breakthroughs years or decades later. - The case study also shows the gap that remains: HIV is treatable, but an effective vaccine still does not exist. - The series lands amid debate over federal science funding, making the case for research support over long timelines.

What happened: - Stand Up for Science released the 10th installment of its weekly “Traces Thursday” series. - The latest case study is titled “HIV infection treatment and prevention.” - The series examines how research on HIV led to drugs that control transmission and infection. - Stand Up for Science said it will keep publishing the series each Thursday on the Science Fight Club Substack.

The details: - HIV first emerged in 1981 as the cause of AIDS, which was then untreatable and led to more than 100,000 deaths by the end of the decade. - Researchers identified HIV as the cause of AIDS a few years later and unlocked the virus’s genomic sequence. - In 1984, the then-Secretary for Health and Human Services estimated a vaccine would be ready for testing within two years. - The first major HIV treatment breakthrough was azidothymidine, or AZT, which blocked viral replication but later faced resistance problems. - Scientists later identified protease, a protein-cleaving enzyme essential to HIV viability, and developed protease inhibitors that also eventually ran into resistance. - In the mid-1990s, researchers reported strong results from combining reverse transcription inhibitors with a protease inhibitor. - That combination transformed HIV infection from a fatal disease into a treatable chronic condition. - Dr. Jeremy Berg said continued research also produced pre-exposure prophylaxis, or PrEP, which dramatically reduced mother-to-child transmission during childbirth. - Berg also said lanacapavir was more effective than PrEP at preventing infection in clinical trials. - Berg is the author of the Traces series, a former director of the National Institute of General Medical Sciences at NIH, a former editor-in-chief of Science magazine, and now a member of Stand Up for Science’s Board of Advisors. - Decades of NIH-funded research have made HIV one of the best-characterized viruses and have informed understanding of other viruses as well. - The case study is part of a planned 12-part series.

Between the lines: - The piece is not just a history of HIV treatment; it is also a broader argument for sustained scientific investment. - The long timeline from discovery to treatment supports the idea that major medical progress often outlasts election cycles and grant periods. - The unfinished vaccine effort underscores how scientific success can coexist with unresolved public health challenges.

What's next: - Stand Up for Science will continue the “Traces Thursday” series with weekly posts. - Berg is available for comment. - The remaining installments will continue building the case study series toward its planned 12-part total. - The organization will keep publishing the series on the Science Fight Club Substack each Thursday.